PCRX - Pacira BioSciences Inc Stock Price, Fair Value and News

$16.51+0.62 (+3.90%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PCRX RSI Chart

PCRX Valuation

Market Cap

761.6M

Price/Earnings (Trailing)

11.98

Price/Sales (Trailing)

1.1

EV/EBITDA

5.27

Price/Free Cashflow

4.12

PCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PCRX Fundamentals

PCRX Revenue

Revenue (TTM)

690.3M

Rev. Growth (Yr)

5.05%

Rev. Growth (Qtr)

6.53%

PCRX Earnings

Earnings (TTM)

63.6M

Earnings Growth (Yr)

-26.69%

Earnings Growth (Qtr)

110.34%

PCRX Price Action

Last 7 days

13.6%

Last 30 days

9.0%

Last 90 days

-21.6%

Trailing 12 Months

-43.2%

PCRX Profitability

Operating Margin

74.05%

EBT Margin

14.57%

Return on Equity

7.23%

Return on Assets

3.86%

Free Cashflow Yield

24.26%

PCRX Financial Health

Current Ratio

6.82

Debt/Equity

0.55

Debt/Cashflow

0.41

PCRX Investor Care

Buy Backs (1Y)

0.62%

Diluted EPS (TTM)

1.36

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	681.8M	690.3M	0	0
2023	669.2M	669.2M	665.7M	675.0M
2022	580.5M	614.3M	654.1M	666.8M
2021	443.0M	503.1M	513.3M	541.5M
2020	435.4M	408.3M	421.1M	429.6M
2019	354.0M	372.5M	393.7M	421.0M
2018	292.0M	305.1M	321.2M	337.3M
2017	280.2M	281.5M	280.5M	286.6M
2016	256.2M	266.6M	272.8M	276.4M
2015	355.2M	367.2M	377.3M	249.0M
2014	110.6M	140.7M	169.4M	333.5M
2013	42.9M	47.7M	62.4M	85.6M
2012	19.6M	28.3M	32.9M	39.1M
2011	13.6M	14.2M	13.6M	15.7M
2010	14.9M	14.8M	14.7M	14.6M
2009	0	0	0	15.0M
2008	0	0	0	13.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Pacira BioSciences Inc

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

CEO	Mr. David M. Stack
WEBSITE	pacira.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	715

Pacira BioSciences Inc Frequently Asked Questions

What is the ticker symbol for Pacira BioSciences Inc? What does PCRX stand for in stocks?

PCRX is the stock ticker symbol of Pacira BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pacira BioSciences Inc (PCRX)?

As of Fri Oct 04 2024, market cap of Pacira BioSciences Inc is 761.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCRX stock?

You can check PCRX's fair value in chart for subscribers.

Is Pacira BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether PCRX is over valued or under valued. Whether Pacira BioSciences Inc is cheap or expensive depends on the assumptions which impact Pacira BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCRX.

What is Pacira BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 04 2024, PCRX's PE ratio (Price to Earnings) is 11.98 and Price to Sales (PS) ratio is 1.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pacira BioSciences Inc's stock?

In the past 10 years, Pacira BioSciences Inc has provided -0.163 (multiply by 100 for percentage) rate of return.